AFT Pharmaceuticals (NZE:AFT, ASX:AFP) said it is on track to meet its fiscal 2026 operating earnings guidance of NZ$20 million to NZ$24 million, according to Thursday filings with the Australian and New Zealand bourses.
The company's Kiwi shares were down 1% in recent Thursday trade.